Prenetics Global Limited - Ordinary Shares - Class A
PRE
Get informed when a big investor buys or sells
+ Follow
Current Fair Value
190.5% downsideOvervalued by 190.5% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $358.71 Million |
|---|---|
| Enterprise Value | $331.87 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-2.68 |
| Beta | 0.15 |
| Outstanding Shares | 16,034,309 |
Return
| Return on Equity | -33.40% |
|---|---|
| Return on Assets | -28.66% |
| Return on Invested Capital | -23.32% |
Valuation & Multiples
| P/E Ratio | -5.8 |
|---|---|
| PEG | -8.05 |
| Price to Sales | 4.17 |
| Price to Book Ratio | 2.08 |
| Enterprise Value to Revenue | 3.49 |
| Enterprise Value to EBIT | -8.09 |
| Enterprise Value to Net Income | -6 |
| Total Debt to Enterprise | 0.02 |
| Debt to Equity | 0.03 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Next Earnings Call
Institutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | 24,900▼ 66.76% |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 12.41%▲ 1.56% |
|---|---|
| Total Invested | $38.46M▲ 40.34% |
| Investors Holding | 35▼ 1.00% |
ESG Score
No data
About Prenetics Global Limited
Relevant Senate Committees
Its technical expertise and 'revenue estimates' directly influence corporate tax structures and policy changes, which can significantly affect the overall tax burden and financial strategies of biotech companies.
This committee controls taxation (impacting corporate valuations) and entitlement spending (e.g., Medicare pricing), which directly affects profitability and market access for healthcare and biotech products.
Its subcommittees allocate federal spending for scientific research (e.g., NIH, CDC), directly determining critical funding streams and grant opportunities for biotech companies.
This committee directly regulates the FDA (critical for product approval) and NIH (key for research funding), which are foundational to the operation and valuation of a biotech company.
This committee's oversight of intellectual property (patents crucial for genetic technologies) and antitrust laws (influencing mergers and competition) directly impacts the biotech industry's legal and competitive landscape.
Members receive classified briefings on global threats, explicitly including risks for 'biotech stocks,' creating high potential for informational asymmetry related to biodefense or emerging health threats.